Baird Medical Secures Regulatory Approvals in Pakistan and Vietnam

Baird Medical (NASDAQ: BDMD) announced on January 7, 2026 that it received official product registrations from the Medical Device Board of Pakistan and the Ministry of Health of Vietnam.

Rhea-AI Summary

Baird Medical (NASDAQ: BDMD) announced on January 7, 2026 that it received official product registrations from the Medical Device Board of Pakistan and the Ministry of Health of Vietnam. The company executed a Pakistan product launch at the Armed Forces Institute of Radiology & Imaging (AFIRI) under the professional guidance of Dr. Raza Raheem.

Vietnam registration expands Baird Medical's compliant footprint in Southeast Asia and supports its stated global commercialization strategy by enabling market entry and clinician access to its microwave ablation (MWA) technology.

Positive

• Regulatory approvals secured in Pakistan and Vietnam on January 7, 2026
• Official product launch completed at AFIRI in Pakistan
• Vietnam approval expands compliant footprint in Southeast Asia

Negative

• None.

Argus Jan 7 session

+3.88% close to close Open Argus

Details

News Market Reaction – BDMD

On Jan 7, the day this news came out, BDMD closed 3.88% above the previous close.

Data tracked by StockTitan Argus for the Jan 7 session.

Market Context

This announcement highlights Baird Medical’s continued international expansion, adding regulatory ap...

Analysis

This announcement highlights Baird Medical’s continued international expansion, adding regulatory approvals and product registration in Pakistan and Vietnam to earlier moves into Egypt, Indonesia, Malaysia, and key U.S. practices. These updates extend the reach of its microwave ablation platform under recognized health authorities. Recent history shows progress in reimbursement, leadership, and manufacturing capacity. Investors may focus on procedure volumes, further regulatory clearances, and adoption trends to gauge how these milestones translate into sustainable commercial growth.

Key Figures

Live MWA procedures: 3 procedures MWA procedures: 9 procedures Bone lesion size: 1 x 1.5 cm +5 more

Live MWA procedures

3 procedures

Training session on Dec. 8, 2025 in Arizona

MWA procedures

9 procedures

Initial thyroid nodule treatments at Brooklyn practice

Bone lesion size

1 x 1.5 cm

First bone tumor ablation in Egyptian market

Patient age

30 years

Male patient in Egyptian bone ablation case

VNUS revenue start

$49M

Revenue level before growth under new leadership

VNUS revenue after growth

>$100M

U.S. revenue after scaling VNUS Medical Technologies

VNUS acquisition value

$512M

Acquisition of VNUS by Covidien

NeuroPace IPO

$117M

IPO size supported by current U.S. CEO in prior role

Historical Context

5 past events · Latest: Dec 17

5 events

1. Dec 17

   Manufacturing expansion

   24h Move

   +2.2%

   Established U.S. manufacturing base via partnership with MPS Medical.

2. Dec 08

   Clinical training

   24h Move

   -4.9%

   Advanced MWA training for Arizona surgeon with live procedures.

3. Dec 03

   Leadership change

   24h Move

   +11.1%

   Appointed veteran medical-device executive as U.S. CEO.

4. Nov 03

   Market entry

   24h Move

   -9.2%

   First successful bone tumor ablation marking Egyptian market entry.

5. Oct 27

   Reimbursement milestone

   24h Move

   +2.1%

   MWA system procedures at NY practice successfully reimbursed by Medicare.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

microwave ablation (mwa), ministry of health, interventional radiology, minimally invasive

4 terms

microwave ablation (mwa) medical

"a market leader in Microwave Ablation (MWA) technology, today announced"

Microwave ablation (MWA) is a minimally invasive medical procedure that uses focused microwave energy to heat and destroy unwanted tissue, such as tumors or lesions, without open surgery. Think of it like using a tiny, precise microwave oven inside the body to remove a problem area; for investors, MWA matters because its effectiveness, safety, costs, and adoption influence demand for related devices, hospital procedures, reimbursement and potential market growth.

ministry of health regulatory

"and the Ministry of Health of Vietnam."

A ministry of health is a government department that sets public health rules, approves or restricts medicines, medical devices and treatments, and runs or oversees health services. Its decisions are like a referee and rulebook for the healthcare market: they determine whether products can be sold, how care is paid for, and how outbreaks or policies affect demand — all of which can materially change a health-related company’s revenues and costs.

interventional radiology medical

"a leading authority in the country's interventional radiology sector."

Interventional radiology is a medical specialty that uses imaging tools (like X-rays, CT scans or ultrasound) as a live map to guide tiny instruments through small skin openings to diagnose or treat problems inside the body, replacing larger surgeries. For investors, it matters because these image-guided procedures often cut recovery time, reduce hospital stays and create steady demand for specialized devices, imaging equipment and related services, affecting healthcare costs and industry revenues.

minimally invasive medical

"advanced, minimally invasive tools to improve outcomes for patients."

Medical procedures described as minimally invasive use small cuts, flexible tubes or tiny cameras to treat or diagnose problems with far less cutting than traditional surgery — like using a keyhole instead of tearing down a wall. Investors care because these approaches can shorten hospital stays, lower complication rates and change equipment and reimbursement needs, which can speed adoption and reshape market demand for devices, supplies and services.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, Jan. 7, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a market leader in Microwave Ablation (MWA) technology, today announced it has reached key regulatory milestones with official product registrations from both the Medical Device Board (MDB) of Pakistan and the Ministry of Health of Vietnam.

In Pakistan, the Company successfully executed its official product launch at the Armed Forces Institute of Radiology & Imaging (AFIRI). The launch was conducted under the professional guidance of Dr. Raza Raheem, a leading authority in the country's interventional radiology sector.

Simultaneously, the registration approval in Vietnam marks a significant expansion of Baird Medical's compliant footprint within the Southeast Asian market. These dual approvals underscore the Company's commitment to accelerating its global commercialization strategy.

"Securing these approvals in Pakistan and Vietnam is a pivotal step in our international expansion," said Mrs. Haimei Wu, Chairwoman of Baird Medical. "By entering these high-growth markets, we are empowering local clinicians with advanced, minimally invasive tools to improve outcomes for patients."

About Baird Medical

Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company will foster strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical's solutions have been used in over 30 prestigious hospitals and clinics across the United States, including Mayo Clinic, Tulane Medical Center, Columbia University Medical Center, UCSF Medical Center, Weill Cornell Medical Center, and The George Washington University Hospital. Baird Medical is also the market leader in China in thyroid microwave ablation devices and consumables. Meanwhile, the company's minimally invasive treatment products are gradually expanding their commercial presence in over 20 countries worldwide.

Forward-Looking Statements

This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "anticipate", "believe", "budget", "forecast", "intend", "plan", "potential", "predict", or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.

Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (6) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled "Risk Factors" therein, and in ExcelFin's other filings with the SEC. 

The foregoing list of factors is not exclusive. Additional information concerning certain of these, and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Contact:
Eric Huang, PR Liaison
Baird Medical Investment Holdings Ltd.
Phone: +1 (888) 508-6228
Email: ir@bairdmed.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-medical-secures-regulatory-approvals-in-pakistan-and-vietnam-302654738.html

SOURCE BDMD

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What approvals did Baird Medical (BDMD) announce on January 7, 2026?

Baird Medical announced official product registrations from the Medical Device Board of Pakistan and the Ministry of Health of Vietnam.

How does the Pakistan product launch affect BDMD's commercialization timeline?

The company executed an official launch at AFIRI, indicating immediate local clinical access and initial market commercialization in Pakistan.

Does the Vietnam registration allow Baird Medical (BDMD) to sell products in Southeast Asia?

The Vietnam approval expands BDMD's compliant footprint in Southeast Asia and enables market entry in that country.

Who guided the Pakistan launch for Baird Medical (BDMD)?

The Pakistan launch at AFIRI was conducted under the professional guidance of Dr. Raza Raheem.

What technology did Baird Medical (BDMD) highlight in the Jan 7, 2026 announcement?

The announcement highlights Baird Medical's microwave ablation (MWA) technology and its use by local clinicians.

Will the approvals announced by BDMD on January 7, 2026 likely affect global expansion?

The company characterized the dual approvals as a pivotal step toward accelerating its global commercialization strategy.